Thrombosis and Ischemic Stroke Prophylaxis
To prevent the development of an ischemic stroke, it is essential to effectively prevent thrombus formation within the vascular bed. For this purpose, modern clinical practice traditionally prescribes two major groups of medications that affect the hemostatic system.
The first group comprises antiplatelet agents. These include widely known drugs such as acetylsalicylic acid, clopidogrel, as well as ticlopidine and dipyridamole. Their primary pharmacological objective is to inhibit the pathological aggregation of platelets during the early stages of thrombus formation.
The second group consists of anticoagulants. These agents directly interfere with the plasma coagulation cascade.
However, the use of these potent drugs is always associated with significant clinical limitations. The most formidable risk of antithrombotic therapy is the induction of intracranial hemorrhage. Therefore, any threat of hemorrhagic stroke serves as an absolute contraindication to prescribing these drug classes. The attending physician must always carefully balance the risk of worsening ischemia against the risk of fatal bleeding.
Combined Therapy for Cerebral Ischemia
When ischemic cerebrovascular disorders have already occurred, monotherapy with a single drug is often insufficient. In such complex situations, combination medications are utilized, a prominent example being Instenon. Its high therapeutic efficacy is due to the pronounced pharmacological synergy of three active components, each with its specific site of action.
- Hexobendine. This component is responsible for rapidly relieving vascular spasm (spasmolytic action). Additionally, it exhibits a proven coronary vasodilating effect, which positively impacts the patient's systemic hemodynamics.
- Etamivan. A substance with a pronounced analeptic profile. It actively stimulates the central nervous system, maintaining the viability and activity of neural networks under conditions of acute oxygen deprivation.
- Etofylline (also known in pharmacology as hydroxyethyltheophylline). Its key function in this combination is the targeted improvement of cerebral blood flow, which is critical for the adequate delivery of oxygen and nutrients to ischemic brain tissues.
Neuroprotective Therapy
Neuroprotective therapy represents an independent and highly vital vector in the comprehensive treatment of cerebral ischemia. Its fundamental goal is to artificially increase the resistance of nerve cells (neurons) to severe hypoxic conditions. To achieve this ambitious goal, drugs from entirely different pharmacological groups are used, acting on various links of the ischemic injury pathogenesis.
- Effects on Tissue Metabolism. A clear example of this approach is sodium oxybate. This drug is capable of altering cerebral metabolism so that nerve tissues tolerate oxygen deprivation much more readily while preserving their structure.
- Blockade of Excitotoxicity. Acute ischemia triggers a massive release of excitatory amino acids, primarily glutamate, which literally "overexcites" and kills neurons. NMDA receptor antagonists (e.g., dizocilpine) effectively block this detrimental effect, preventing cell death.
- Regulation of Calcium Homeostasis. Here, calcium channel blockers come to the forefront. They are unique in providing a potent dual therapeutic effect. On one hand, they dilate blood vessels and improve local blood flow. On the other hand, they provide true cellular neuroprotection by sharply reducing the pathological influx of calcium ions into damaged cells.
- Other Neuroprotective Agents. The arsenal of neurologists and pharmacologists also includes vinpocetine, a drug that, alongside its established vascular effects, possesses reliably proven neuroprotective properties.